During his tenure at BioMarin, Bienaimé steered BioMarin from ... “With nearly three decades experience as CEO, Mr Bienaimé’s proven track record and visionary leadership will inspire ...

Earnings Call Insights: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2024 CEO Alexander Hardy emphasized that 2024 marked a year of record growth and profitability for BioMarin, with revenue ...

Walbert, the former chairman, president, and CEO of Horizon Therapeutics (NASDAQ:HZNP), brings over three decades of experience in the pharmaceutical industry to BioMarin's board. According to ...

BioMarin's resources did not go unnoticed by the deal-hungry biotech community. “We had 155 meetings at J.P. Morgan,” CEO Alexander Hardy said on the company’s Feb. 19 earnings call.

Brian Mueller, Chief Financial Officer; Cristin Hubbard, Chief Commercial Officer; and Greg Friberg, Chief R&D Officer. I will now turn the call over to BioMarin's President and CEO, Alexander Hardy.

In summary, we expect continued high performance as we benefit from BioMarin's revamped corporate strategy and operating model in 2025 and beyond," said Alexander Hardy, President and CEO of BioMarin.

“Our operational transformation and strong financial execution in 2024 is the first step in BioMarin’s ambitious multiyear growth plan,” Alexander Hardy, president and CEO, said in a statemen ...

Can you give a brief, state of the company overview, biggest strengths, biggest challenges and what does BioMarin need to achieve to drive shareholder value over the next twelve to twenty four months?

Walbert, the former chairman, president, and CEO of Horizon Therapeutics (NASDAQ:HZNP), brings over three decades of experience in the pharmaceutical industry to BioMarin's board. According to ...

CEO Alexander Hardy emphasized that 2024 marked a year of record growth and profitability for BioMarin, with revenue increasing by 18% year-over-year and non-GAAP diluted EPS up 69%. He ...